Therachon
Webb25 mars 2024 · BASEL, Switzerland, March 25, 2024 /PRNewswire/ -- Therachon AG ("Therachon"), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative ... WebbTherachon is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe, rare conditions …
Therachon
Did you know?
Webb8 maj 2024 · Therachon is developing it as a weekly subcutaneous injection for children and adolescents with the disorder. The drug has finished Phase I trials. The European … Webb17 maj 2024 · Therachon is a clinical-stage global biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe, rare conditions for which there is ...
Webb1 juli 2024 · Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of the privately held clinical-stage biotechnology company Therachon Holdin Webb13 mars 2024 · Therachon was focused on the discovery and development of therapeutics for rare pediatric conditions, and was acquired by Pfizer, Inc., in 2024 for $810 million. …
Webb5 sep. 2024 · Therachon Holding AG has developed products for the treatment of achondroplasia and short bowel syndrome.These include product candidate TA-46 for the treatment of achondroplasia, “a genetic condition and the most common form of short-limbed dwarfism”, as was reported in a press release from Pfizer.The U.S. … Webb17 aug. 2024 · Swiss-based biotech company, Therachon, which focuses on developing rare genetic disease treatments, says it has closed a $60 million round of funding as the company moves closer to a drug trial. The funding will be used to develop the company’s treatment for achondroplasia, the most common form of short limbed dwarfism, and …
WebbTherachon is a global biotechnology company focused on developing medicines for rare, genetic diseases that currently have no available treatments. The company’s lead …
Webb30 jan. 2024 · BASEL, Switzerland, Jan. 30, 2024 /PRNewswire/ -- Therachon AG ("Therachon"), a clinical-stage biotechnology company focused on the discovery, development and commercialization of innovative ... norovirus outbreak checklistWebb8 jan. 2024 · The founders of Swiss biotech Therachon have launched a new company called VectivBio, also based in Basel, with €31M funding to develop drugs for rare … how to remove workbook linksWebb9 okt. 2024 · BASEL, Switzerland, Oct. 9, 2024 /PRNewswire/ -- Therachon AG ("Therachon"), a clinical-stage biotechnology company focused on treating root causes of rare conditions, today announced the ... norovirus outbreak 2023 mapWebbPfizer is set to pay $340 million (€304 million) upfront to buy Therachon for Pfizer is set to pay $340 million (€304 million) upfront to buy Therachon for its treatment for a form of … norovirus news 2022Webb31 jan. 2024 · The investigational drug, one of an early generation drummed up by the buzzy AI tools in biotech, works by inhibiting multiple tropomyosin-related kinases, which … norovirus outbreak cincinnatiWebb9 maj 2024 · May 9, 2024 - Updated on June 24, 2024. 2 minutes. Pharma giant Pfizer is acquiring the Swiss biotech Therachon, which is developing a protein drug to boost bone growth in the genetic condition achondroplasia. Pfizer will pay €303M ($340M) upfront, and up to €420M ($470M) dependent on Therachon reaching milestones in the development … norovirus outbreak nowhttp://therachon.com/research/ norovirus outbreak in uk